Hasil Pengobatan dan Variasi Biaya TB-MDR/XDR dengan Strategi PMDT di RSUP Persahabatan
Abstract
Keywords
Full Text:
PDFReferences
(1) World Health Organization (WHO). (2012). Global Tuberculosis Control. WHO: Geneva,Switzerland.
(2) World Health Organization (WHO). (2010). Guideline for the Programmatic Management of Drug-Resistant Tuberculosis. WHO: Emergency Update.
(3) Aditama TY. (2012). Permasalahan Kasus TB-MDR di Indonesia Pengendali-an Penyakit Penyehatan Lingkungan (PP dan PL), Kementerian Kesehatan Republik Indonesia dalam .
(4) Kementerian Kesehatan Republik Indonesia. (2013). Peraturan Menteri Kesehatan Republik Indonesia Nomor 13 Tahun 2013 tentang Pedoman Manjemen Terpadu Pengendalian Tuberkulosis Resistan Obat. Republik Indonesia: Kementerian Kesehatan.
(5) Kementerian Kesehatan RI Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan (PP dan PL). (2011). Stop TB Rencana Aksi Nasion-al. Programatic Mangement of Drug Resistance Tuberculosis Pengendalian Tuberculosis, Indonesia 2011- 2014. Jakarta: Kementerian Kesehatan.
(6) World Health Organization (WHO) Regional Office for South Asia. (2011). Drug Resistant Tuberculosis in the South Asia Region Report. New Delhi: WHO dalam .
(7) Blog Khusus makalah. Pengertian, Konsep, dan Jenis biaya dalam .
(8) Mulyadi. (2012). Akuntansi Biaya Edisi 5. UPP STIM YKPN.
(9) Bashar M, Alcabes P, Rom WN, Condos R. (2001). Increased Incidence of Multidrug-Resistant Tuberculosis in Diabetic Patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001;120:1514-19.
(10) Aditama TY. (2013). Pengendalian Tuberkulosis di Indonesia Menuju Strategi Post 2015. Jakarta: Simposium Nasional Hari TB sedunia.
(11) Tupasi E, Gupta R, Quelapio ID, Orillaza RB, Mira NR, Mangubat NV et all. (2006). Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the Phlippines. Plos Medicine 2006; 3: 1-17
(12) Suarez PG, Portocarrero J, Alarcon E, Rapiti E, Ramos G, Bonila C et all. (2002). Feasibility and Cost-Effectiveness of Standardised Second-Line Drug Treatment for Chronic Tuberculosis Patients: A National Cohort Study in Peru. Lancet 2002; 359: 1980–89.
(13) Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsui CJ. (2006). Outcome of Multidrug-Resistant Tuberculosis; a 6-yr Follow up Study. Eur Respir J 2006;28:980-85.
(14) Perhimpunan Dokter Paru Indonesia. (2013). Pedoman Kelayakan Bekerja Bagi PenderitaTuberkulosis Paru di Indonesia. Jakarta.
(15) Ascobat Gani. (1994). Aspek Ekonomi Pelayananan Kesehatan. Cermin Dunia Kedokteran, Edisi khusus no.90 1994; 34-40.
(16) Soepandi, Priyanti. (2013). Hasil Pengobatan dan Variasi Biaya TB-MDR/XDR dengan Strategi Programmatic Management of Drug Resistant Tubercu-losis (PMDT). Depok: Fakultas Kesehatan Masyarakat Universitas Indonesia.
DOI: http://dx.doi.org/10.7454/arsi.v1i1.2166
Refbacks
- There are currently no refbacks.